LPKF Opens Biolab for ARRALYZE Technology
ARRALYZE combines biomedical research with software and precision technology. The system can thus contribute to the accelerated development of personalized medicine, for example in the field of cancer therapies.
Dr. Robin Krueger is the head of ARRALYZE. He studied chemistry and biochemistry and worked early on with optically switchable proteins in hospital germs. "We know that tumors have individual characteristics and are influenced by genes and other physiological properties. For this reason, no one should get a standard cancer therapy, but one that is tailored to them personally." Krueger and his team of collaborators are convinced that ARRALYZE will make the development of modern medication much more cost-effective, thus enabling the widespread use of personalized medicine.
The recently opened biolab is equipped with specialized equipment for the production and analysis of cell cultures. "The biolab is essential for us to understand the needs and problems of our ARRALYZE customers and to be able to offer practical solutions," says Krueger. "This is what sets us apart from other plant growers in this complex field."
For Britta Schulz, member of the Management Board and head of the Development segment, the development of ARRALYZE technology in less than 3 years is a demonstration to LPKF's unwavering innovative strength. "With our LIDE technology for structuring glass and our expertise in optics, precision engineering and software, we are now bringing a product to market that will set new standards in biotechnology," says Schulz.
The system is thus one more step towards pushing back the previous boundaries of cell biology. The innovative approach of this process qualified ARRALYZE for inclusion in the shortlist of the prestigious Innovation Award 2021 of the State of Lower Saxony.
Further information on the technology and the platform can be found at www.arralyze.com